natgillin/translations-raw huggingface dataset:
• Serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
• resne alergijske reakcije, kot je reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS - Drug Reaction with Eosinophilia and Systemic Symptoms).
• diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma
• sladkorno bolezen ali poslabšanje sladkorne bolezni, občasno povezano s ketoacidozo (ketoni v krvi in urinu) ali komo,
Glucosuria
glukozurija
If you take more Olanzapine Glenmark Europe than you should Patients who have taken more Olanzapine Glenmark Europe than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Če ste vzeli večji odmerek zdravila Olanzapin Glenmark Europe, kot bi smeli Bolniki, ki so vzeli večji odmerek zdravila Olanzapin Glenmark Europe, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
In patients with Parkinson's disease Olanzapine Glenmark Europe may worsen the symptoms
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olanzapin Glenmark Europe poslabša simptome.
Dementia-related psychosis and/or behavioural disturbances Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Psihoza povezana z demenco in/ali vedenjske motnje Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range.
Pri večini teh bolnikov je bilo povečanje navadno blago in ni preseglo dvakratne koncentracije zgornje meje normalne vrednosti.
• seizures, usually associated with a history of seizures (epilepsy)
• krče, običajno povezane s krči (epileptičnimi napadi) v preteklosti,
If you forget to take Olanzapine Glenmark Europe Take your tablets as soon as you remember.
Če ste pozabili vzeti zdravilo Olanzapin Glenmark Europe Vzemite tablete, kakor hitro se spomnite.
Olanzapine Glenmark Europe has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
Zdravilo Olanzapin Glenmark Europe dokazano preprečuje ponoven pojav teh simptomov pri bolnikih z bipolarno motnjo, pri katerih se je manična epizoda po zdravljenju z olanzapinom izboljšala.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.
Nevroleptični maligni sindrom (NMS) NMS je potencialno življenje ogrožajoče stanje, povezano z antipsihotiki.
You can also place the tablet in a full glass or cup of water or other suitable beverage (orange juice, apple juice, milk or coffee) and stir.
Tableto lahko daste tudi v poln kozarec ali skodelico vode ali v drugo primerno pijačo (pomarančni sok, jabolčni sok, mleko ali kava) in tekočino premešate.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark Europe unless your doctor tells you to.
Če se simptomi povrnejo, se posvetujte s svojim zdravnikom, vendar ne prenehajte jemati zdravila Olanzapin Glenmark Europe, če vam tega ne naroči vaš zdravnik.
• Hair loss.
• izgubo las,
- Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness.
Zelo redko tovrstna zdravila povzročijo kombinacijo zvišanja telesne temperature, pospešenega dihanja, znojenja, okorelosti mišic in dremavosti ali zaspanosti.
The daily dose of Olanzapine Glenmark Europe is between 5 mg and 20 mg.
Dnevni odmerek zdravila Olanzapin Glenmark Europe je med 5mg in 20 mg.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najpogosteje poročani (opaženi pri ≥ 1 % bolnikov) neželeni učinki, povezani z uporabo olanzapina v kliničnih preskušanjih, so bili zaspanost, povečanje telesne mase, eozinofilija, zvišane ravni prolaktina, holesterola, glukoze in trigliceridov (glejte poglavje 4.4), glukozurija, povečan apetit, omotica, akatizija, parkinsonizem, levkopenija, nevtropenija (glejte poglavje 4.4), diskinezija, ortostatska hipotenzija, antiholinergični učinki, prehodna asimptomatska zvišanja jetrnih aminotransferaz (glejte poglave 4.4), izpuščaj, astenija, utrujenost, pireksija, artralgija, zvišana alkalna fosfataza, visoka raven gama-glutamiltransferaze, visoka raven sečne kisline, visoka raven kreatinfosfokinaze in edem.
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
Študija je pokazala, da je bilo tveganje pri olanzepinu primerljivo s tveganjem pri atipičnih antipsihotikih, vključenih v skupno analizo.
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
hepatitis (vključno s hepatocelularn o, holestatsko ali mešano okvaro jeter)11
It is important that you carry on taking Olanzapine Glenmark Europe for as long as your doctor tells you.
Pomembno je, da nadaljujete z jemanjem zdravila Olanzapin Glenmark Europe tako dolgo, kot vam naroči zdravnik.
• Hypersensitivity (e.g. swelling in the mouth and throat, itching, rash)
• preobčutljivost (npr. otekanje v ustih in grlu, srbenje, izpuščaj),
Aluminium/aluminium blisters in cartons of 28, 56, 70 tablets per carton.
Aluminij/aluminij pretisni omoti v škatlah po 28, 56 ali 70 tablet.
What Olanzapine Glenmark Europe is and what it is used for What you need to know before you take Olanzapine Glenmark Europe How to take Olanzapine Glenmark Europe Possible side effects
Kaj je zdravilo Olanzapin Glenmark Europe in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Glenmark Europe Kako jemati zdravilo Olanzapin Glenmark Europe Možni neželeni učinki
Metabolism and nutrition disorders Weight gain1 Elevated cholesterol levels2,3
Presnovne in prehranske motnje povečanje telesne mase1 zvišane ravni holesterola2,3
Urinary incontinence, urinary retention
• urinsko inkontinenco,
Keep this medicine out of sight and reach and of children
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ POGLEDA IN DOSEGA OTROK
Olanzapine is not indicated for use in the treatment of children and adolescents.
Pediatrična populacija Olanzapin ni indiciran za uporabo pri zdravljenju otrok in mladostnikov.
• Liver disease appearing as yellowing of the skin and white parts of the eyes.
• ki se kaže kot obarvanje kože in beločnic na rumeno,
Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section
trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje
You should take your Olanzapine Glenmark Europe orodispersible tablets once a day following the advice of your doctor.
Zdravilo Olanzapin Glenmark Europe orodisperzibilne tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Olanzapine Glenmark Europe 5 mg, 10 mg, 15 mg and 20 mg are available in aluminium foil blisters of 28, 56, and 70 orodispersible tablets
Olanzapin Glenmark Europe 5 mg, 10 mg, 15 mg in 20 mg orodisperzibilne tablete so na voljo v aluminijastih pretisnih omotih po 28, 56 in 70 orodisperzibilnih tablet.
However, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.
Vendar pa je potrebna previdnost, kadar predpisujemo olanzapin skupaj z zdravili, za katera je znano, da podaljšujejo QTc interval, posebno pri starejših, pri bolnikih s prirojenim sindromom dolgega QT intervala, kongestivnim popuščanjem srca, hipertrofijo srca, hipokaliemijo ali hipomagneziemijo.
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4).
V kliničnih preskušanjih pri starejših bolnikih z demenco je bilo zdravljenje z olanzapinom povezano z višjo incidenco smrti in cerebrovaskularnih neželenih učinkov v primerjavi s placebom (glejte poglavje 4.4).
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom Olanzapin Glenmark Europe, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
What you need to know before you take Olanzapine Glenmark Europe
Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Glenmark Europe
Olanzapine Glenmark Europe orodispersible tablets are for oral use.
Orodisperzibilne tablete Olanzapin Glenmark Europe so za peroralno uporabo.
If you suddenly stop taking Olanzapine Glenmark Europe, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Če nenadno prenehate jemati zdravilo Olanzapin Glenmark Europe, se lahko pojavijo simptomi, kot so znojenje, nespečnost, tresenje, občutek tesnobe ali slabost in bruhanje.
What Olanzapine Glenmark Europe is and what it is used for
Kaj je zdravilo Olanzapin Glenmark Europe in za kaj ga uporabljamo
• Slow heart rate.
• upočasnjen srčni utrip,
Decreased libido in males and females
Erektilna disfunkcija pri moških Zmanjšan libido pri moških in ženskah
This includes any possible side effects not listed in this leaflet.
Posvetujte se tudi, če opazite katerekoli neželene učinke, ki niso navedeni v tem navodilu Glej točko 4.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark Europe in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Olanzapin Glenmark Europe, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α 1 adrenergic; and histamine H1 receptors.
V predkliničnih študijah je olanzapin pokazal razpon afinitet do receptorjev (Ki < 100 nM) za serotonin 5-HT2A/2C, 5-HT3, 5-HT6; dopamin D1, D2, D3, D4, D5; holinergičnih muskarinskih receptorjev M1-M5; adrenergičnih α1; in histaminskih H1 receptorjev.
Reproductive toxicity Olanzapine had no teratogenic effects.
Vpliv na sposobnost razmnoževanja Olanzapin ni imel teratogenih učinkov.
70 orodispersible tablets
70 orodisperzibilnih tablet
Discontinuation symptoms7, 12
odtegnitveni simptomi712
Ventricular tachycardia/fibrillation, sudden death (see section 4.4)11
prekatna tahikardija/fibr ilacija, nenadna smrt (glejte poglavje 4.4)11
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, alaninske transferaze (ALT) in aspartatne transferaze (AST), posebno na začetku zdravljenja.
Olanzapine Glenmark Europe 5 mg orodispersible tablets Olanzapine Glenmark Europe 10 mg orodispersible tablets Olanzapine Glenmark Europe 15 mg orodispersible tablets Olanzapine Glenmark Europe 20 mg orodispersible tablets
Olanzapin Glenmark Europe 5 mg orodisperzibilne tablete Olanzapin Glenmark Europe 10 mg orodisperzibilne tablete Olanzapin Glenmark Europe 15 mg orodisperzibilne tablete Olanzapin Glenmark Europe 20 mg orodisperzibilne tablete olanzapin
Mild, transient anticholinergic effects including constipation and dry mouth
Bolezni prebavil blagi prehodni antiholinergičn i učinki, vključno z zaprtjem in suhimi usti
56 orodispersible tablets
56 orodisperzibilnih tablet
In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % versus 1.5 %, respectively).
V kliničnih preskušanjih, kontroliranih s placebom (ki so trajali 6-12 tednov), pri starejših bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami (povprečna starost 78 let), je bilo 2-kratno povečanje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3,5 % v primerjavi z 1,5 %).
Elevated glucose levels4
zvišane ravni glukoze4
There is no specific antidote for olanzapine.
Ravnanje Za olanzapin ni specifičnega antidota.
Olanzapine Glenmark Europe orodispersible tablet contains aspartame, which is a source of phenylalanine.
Zdravilo Olanzapin Glenmark Europe orodisperzibilne tablete vsebuje aspartam, ki je vir fenilalanina.
28 orodispersible tablets
28 orodisperzibilnih tablet
14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high
14Opazovano pri osnovnih normalnih ravneh na tešče (< 1,016 mmol/l), ki so se povišale na visoke
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value.
8V kliničnih preskušanjih, ki so trajala do 12 tednov, so pri 30 % bolnikov z normalno začetno vrednostjo prolaktina, ki so se zdravili z olanzapinom, ugotovili povečanje plazemske koncentracije prolaktina nad zgornjo mejo normalne vrednosti.
Olanzapine Glenmark Europe contains aspartame Olanzapine Glenmark Europe contains a source of phenylalanine.
Zdravilo Olanzapin Glenmark Europe vsebuje aspartam Zdravilo Olanzapin Glenmark Europe vsebuje vir fenilalanina.
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)
Bolezni jeter, žolčnika in žolčevodov prehodna asimptomatska zvišanja jetrnih aminotransfera z (ALT, AST), posebno na začetku zdravljenja (glejte poglavje 4.4)
Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
Zaviranje CYP1A2 Fluvoksamin, specifični zaviralec CYP1A2, je pokazal pomembno zaviranje presnove olanzapina.
20 mg olanzapine - The other ingredients are mannitol (E 421), microcrystalline cellulose, aspartame (E 951),
Pomožne snovi so manitol (E 421), mikrokristalna celuloza, aspartam (E 951), krospovidon, magnezijev stearat.
Olanzapine Glenmark Europe belongs to a group of medicines called antipsychotics.
Zdravilo Olanzapin Glenmark Europe spada v skupino zdravil, imenovanih antipsihotiki in se uporablja za zdravljenje naslednjih bolezni:
(≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to high (≥ 1.467 mmol/l).
(≥ 1,467 mmol/l) in spremembe v ravneh trigliceridov na tešče z mejnih osnovnih vrednosti (≥ 1,016 mmol/l - < 1,467 mmol/l) na visoke (≥ 1,467 mmol/l).
Do not drink any alcohol if you have been given Olanzapine Glenmark Europe as together with alcohol it may make you feel drowsy.
Jemanje zdravila Olanzapin Glenmark Europe skupaj alkoholom Če ste dobili zdravilo Olanzapin Glenmark Europe, ne pijte nobenega alkohola, saj lahko zdravilo Olanzapin Glenmark Europe in alkohol skupaj povzročita občutek zaspanosti.
• Restless legs syndrome
• sindrom nemirnih nog
Neuroleptic malignant syndrome (see section
Sindrom nemirnih nog nevroleptični maligni sindrom (glejte poglavje odtegnitveni simptomi712
What Olanzapine Glenmark Europe looks like and contents of the pack
Izgled zdravila Olanzapin Glenmark Europe in vsebina pakiranja
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term-exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Zvečanje osnovne telesne mase za ≥ 7 %, ≥ 15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v 64,4 %, 31,7 % in 12,3 %).
If you are pregnant or breast feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden vzamete to zdravilo Ko dojite, tega zdravila ne smete jemati, ker lahko majhne količine zdravila Olanzapin Glenmark Europe prehajajo v materino mleko.
Very common: Weight gain 13, elevated triglyceride levels 14, increased appetite.
Zelo pogosti: povečanje telesne mase13, zvišane ravni trigliceridov14, povečan apetit Pogosti: Zvišane ravni holesterola15
Tardive dyskinesia11
Tardivne diskinezije11
Very common: Weight gain13, elevated triglyceride levels 14, increased appetite.
Zelo pogosti: povečanje telesne mase13, zvišane ravni trigliceridov14, povečan apetit Pogosti: zvišane ravni holesterola15
Nervous system disorders Somnolence Dizziness Akathisia6
Bolezni živčevja zaspanost omotica akatizija6
There is a risk of feeling drowsy when you are given Olanzapine Glenmark Europe.
Vpliv na sposobnost upravljanja vozil in strojev Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olanzapin Glenmark Europe, počutili zaspane.
Parkinsonism6
parkinsonizem diskinezije6
Rare side effects (may affect up to 1 in 1000 people) include:
Redki neželeni učinki (lahko prizadenejo do 1 od 1.000 bolnikov) vključujejo
Uncommon side effects (may affect up to 1 in 100 people) include:
• Občasni neželeni učinki(lahko prizadenejo do 1 od 100 bolnikov) vključujejo
How to store Olanzapine Glenmark Europe
Shranjevanje zdravila Olanzapin Glenmark Europe
If you get any side effects, talk to your doctor or pharmacist.
Če opazite katerikoli neželeni učinek, se posvetuje s svojim zdravnikom ali s farmacevtom.
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section
Razvoj ali poslabšanje sladkorne bolezni, občasno povezane s ketoacidozo ali komo, vključno z nekaj smrtnimi primeri (glejte hipotermija12
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥
13S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 %
Very rare side effects (may affect up to 1 in 10,000) include:
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov) vključujejo:
Reversible neutropenia, thrombocytopenia, or anemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Pri nekaj psih, ki so prejemali 8 ali 10 mg/kg/dan (celotno izpostavljanje olanzapinu [AUC] je 12- do 15-krat večje kot pri človeku, ki dobi 12-miligramski odmerek), se je razvila reverzibilna nevtropenija, trombocitopenija ali anemija.
- High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Glenmark Europe.
Pri bolnikih, ki so jemali zdravilo Olanzapin Glenmark Europe, so opazili visok nivo sladkorja v krvi in visok nivo maščob (trigliceridov in holesterola).
• Heart disease
Žilne bolezni
What Olanzapine Glenmark Europe contains
Kaj vsebuje zdravilo Olanzapin Glenmark Europe
phosphokinase11
Trombocitop enija11
Ventricular tachycardia/fibrillation, sudden death (see section
Srčne bolezni bradikardija podaljšanje QTc (glejte poglavje prekatna tahikardija/fi brilacija, nenadna smrt (glejte poglavje
Yellow coloured circular flat bevelled edge tablets with ‘B' debossed on one side.
Rumene, okrogle, ploščate tablete z zaobljenim robom in oznako 'B' na eni strani.
15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15Pogosto so opazovali spremembe v ravneh celokupnega holesterola na tešče z normalnih osnovnih vrednosti (< 4,39 mmol/l), ki so se povišale na visoke (≥ 5,17 mmol/l).
Talk to your doctor or pharmacist before you take Olanzapine Glenmark Europe - The use of Olanzapine Glenmark Europe in elderly patients with dememtia is not recommended as it may have serious side effects.
Uporaba zdravila Olanzapin Glenmark Europe ni priporočljiva pri starejših bolnikih z demenco, saj lahko povzroči resne neželene učinke.
Marketing Authorisation Holder Glenmark Arzneimittel GmbH Industriestr.
IMETNIK DOVOLJENJA ZA PROMET Glenmark Arzneimittel GmbH Industriestr.
• Inflammation of the pancreas causing severe stomach pain, fever and sickness.
• ki povzroča hude bolečine v predelu želodca, zvišano telesno temperaturo in slabost, obolenje jeter,
Rhabdomyolysis11
Rabdomioliz a11
• Unusual movements (dyskinesias).
nenavadne gibe (diskinezijo),
Olanzapine Glenmark Europe 5mg is supplied as: yellow coloured circular flat bevelled edge orodispersible tablets with ‘B' debossed on one side.
Olanzapin Glenmark Europe 5 mg je na voljo kot: rumena, okrogla, ploščata tableta z zaobljenim robom in oznako 'B' na eni strani.
Olanzapine Glenmark Europe 20 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘F' debossed on other side.
Olanzapin Glenmark Europe 20 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako 'F' na drugi strani.
Increased total bilirubin levels8
Visoka raven zvišan celokupni bilirubin gamaglutamiltransfe raze10